TCZ, a humanized IgG1 monoclonal antibody targeting the IL-6R [35], was shown to effectively reduce depressive and anxiety symptoms, with a sustained downward trend observed in more than 65% of RA patients [17]. Here, IL6R is linked to rheumatoid arthritis.